Virpax Pharmaceuticals (VRPX) surged in recent Friday trading after the specialty medications company said injections of its Probudur drug candidate into tissue surrounding an incisional wound provided both immediate and extended pain relief in minipigs during preclinical testing to determine optimal dosing ranges.
All of the minipigs in the study showed positive tolerance to Probudur and had no adverse effects. Based on the positive results, Virpax said it would continue to work on developing human trials for Probudur as part of an eventual investigational new drug application.
The company's shares were up 47% in recent trading Friday.
Price: 0.83, Change: +0.26, Percent Change: +47.50
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。